⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ProKidney Corp. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ProKidney Corp.
↗Winston-Salem, USA
ProKidney is a late-clinical-stage biotechnology company pioneering a novel autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) at high risk of kidney failure. The company focuses on filling a critical treatment gap for patients whose only other options are dialysis or kidney transplant.
ProKidney's lead product candidate, rilparencel (also known as REACT), is a first-of-its-kind, proprietary, autologous cell therapy. By using a patient's own kidney cells, the therapy aims to stabilize or improve kidney function without the need for immunosuppressive therapy.
CLASSIFICATION
SIZE & FINANCIALS
Founded:2015
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:PROK
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Cell therapy
Active Trials:1
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Bruce Culleton - CEO
Kenneth Locke - Chief Technical Officer
Greg Madison - Chief Commercial Officer
LINKS
Website:prokidney.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ProKidney Corp.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.